RFK Jr. and Dr. Oz to unveil efforts to restrict gender‑affirming care for minors
The Trump administration is slated to release a package of policy measures on Thursday that would effectively prohibit gender‑affirming medical treatment for transgender youth across the United States, even in states that currently permit such care. The announcement is expected to be made alongside public statements from political figures Robert F. Kennedy Jr. and Dr. Oz, who have been vocal supporters of the initiative.
The proposed actions include a new rule that would classify hormone therapy and related procedures for minors as experimental, thereby restricting Medicaid reimbursement and limiting access to private insurance coverage. In addition, the administration plans to direct the Department of Health and Human Services to issue guidance urging hospitals and clinics to halt such treatments pending further review. Officials indicated that the measures aim to protect children from what they describe as irreversible medical interventions.
Advocates for transgender rights have warned that the policy could force young people to discontinue essential care, potentially leading to increased rates of mental‑health crises. Legal experts predict that the rule is likely to face challenges in federal court on grounds of violating existing civil‑rights protections. The Department of Justice, however, has signaled its intent to defend the administration’s position, citing a mandate to safeguard minors.
Background on the issue shows a growing national debate. Over the past decade, several states have enacted laws either limiting or expanding access to gender‑affirming services for youths, creating a patchwork of regulations. Federal involvement has been limited, with previous administrations issuing non‑binding guidance rather than enforceable rules. The current move marks a shift toward a more centralized approach.
Reaction from medical professionals has been largely cautious, emphasizing the importance of evidence‑based care and the potential harms of blanket bans. A spokesperson for a leading pediatric association noted that decisions about treatment should be individualized and involve qualified health‑care providers, patients, and families.
Looking ahead, the administration’s proposal is set to undergo a public comment period before any final rule is issued, a process that could extend over several months. Stakeholders on both sides of the issue are preparing for a prolonged policy battle that will likely influence the broader national conversation on transgender health care and the role of federal authority in regulating medical practices for minors.
